Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy S Putnam

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Journal of Clinical Pharmacology|March 22, 2005
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokineticsWendy S Putnam, Jonathan M Woo, Yong Huang, et al.
Pharmaceutical Research|February 12, 2002
Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transportersWendy S Putnam, Lin Pan, Ken Tsutsui, et al.
Trends in Biotechnology|August 10, 2010
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodiesWendy S Putnam, Saileta Prabhu, Yanan Zheng, et al.
Journal of Pharmaceutical Sciences|November 16, 2002
Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cellsWendy S Putnam, Srinivasan Ramanathan, Lin Pan, et al.
Advances in Therapy|August 16, 2017
A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult VolunteersLin Pan, Paula Belloni, Han Ting Ding, et al.
The AAPS Journal|February 16, 2013
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapyRui Zhu, Yanan Zheng, Wendy S Putnam, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2013
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsMichael Noonan, Phillip Korenblat, Sofia Mosesova, et al.
Drugs in R&D|September 11, 2020
Comparability Considerations and Challenges for Expedited Development Programs for Biological ProductsSarah J Schrieber, Wendy S Putnam, Edwin Chiu Yuen Chow, et al.
Pulmonary Pharmacology & Therapeutics|August 28, 2017
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthmaRui Zhu, Yanan Zheng, Nathanael L Dirks, et al.
The AAPS Journal|August 8, 2008
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibodyWendy S Putnam, Jing Li, Jonas Haggstrom, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Journal of Clinical Pharmacology|March 22, 2005
Effect of the MDR1 C3435T variant and P-glycoprotein induction on dicloxacillin pharmacokineticsWendy S Putnam, Jonathan M Woo, Yong Huang, et al.
Pharmaceutical Research|February 12, 2002
Comparison of bidirectional cephalexin transport across MDCK and caco-2 cell monolayers: interactions with peptide transportersWendy S Putnam, Lin Pan, Ken Tsutsui, et al.
Trends in Biotechnology|August 10, 2010
Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodiesWendy S Putnam, Saileta Prabhu, Yanan Zheng, et al.
Journal of Pharmaceutical Sciences|November 16, 2002
Functional characterization of monocarboxylic acid, large neutral amino acid, bile acid and peptide transporters, and P-glycoprotein in MDCK and Caco-2 cellsWendy S Putnam, Srinivasan Ramanathan, Lin Pan, et al.
Advances in Therapy|August 16, 2017
A Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult VolunteersLin Pan, Paula Belloni, Han Ting Ding, et al.
The AAPS Journal|February 16, 2013
Population-based efficacy modeling of omalizumab in patients with severe allergic asthma inadequately controlled with standard therapyRui Zhu, Yanan Zheng, Wendy S Putnam, et al.
The Journal of Allergy and Clinical Immunology|June 4, 2013
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroidsMichael Noonan, Phillip Korenblat, Sofia Mosesova, et al.
Drugs in R&D|September 11, 2020
Comparability Considerations and Challenges for Expedited Development Programs for Biological ProductsSarah J Schrieber, Wendy S Putnam, Edwin Chiu Yuen Chow, et al.
Pulmonary Pharmacology & Therapeutics|August 28, 2017
Model-based clinical pharmacology profiling and exposure-response relationships of the efficacy and biomarker of lebrikizumab in patients with moderate-to-severe asthmaRui Zhu, Yanan Zheng, Nathanael L Dirks, et al.
The AAPS Journal|August 8, 2008
Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibodyWendy S Putnam, Jing Li, Jonas Haggstrom, et al.
Pageof 3